Added to YB: 2026-07-01
Pitch date: 2026-06-29
CADL [neutral]
Candel Therapeutics, Inc.
-1.34%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.
Market Cap
$717.3M
Pitch Price
$10.44
Price Target
30.00
Dividend
N/A
EV/EBITDA
-10.46
P/E
-10.06
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
BIOTECH MARKET RESEARCH $CADL | Ep. 1029
CADL (overview): Catalyst-driven setup into expected Q4 2026 BLA for aglatimagene in localized prostate cancer. P3 hit DFS HR 0.70 (p=0.0155), PCa-specific DFS HR 0.61. Bear: no OS benefit, low-event downstream data. Trades $9.79, analyst PT $9-30, options imply ±80% move. ~$195M cash to Q1'28; 21.7% short.
Read full article (29 min)